3D Global Biotech Inc. (TPEX:6808)
Taiwan · Delayed Price · Currency is TWD 28.65
-0.35 (-1.21%)
May 29, 2026, 1:35 PM CST
3D Global Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 66.53 | 91.7 | -57.95 | -67.09 | -59.71 |
Depreciation & Amortization | 27.55 | 21.82 | 22.74 | 25.58 | 24.59 |
Other Amortization | 0.1 | 0.02 | 0.15 | 0.29 | 0.29 |
Loss (Gain) From Sale of Assets | - | -0 | - | - | - |
Asset Writedown & Restructuring Costs | - | - | - | 18.89 | - |
Stock-Based Compensation | 3.16 | 4.21 | 0.12 | 0.28 | 0.6 |
Provision & Write-off of Bad Debts | 2.77 | 0.21 | - | - | - |
Other Operating Activities | -14.1 | 3.1 | -0.98 | -16.08 | -1 |
Change in Accounts Receivable | 44.76 | -118.41 | -0.25 | 0.14 | 0.42 |
Change in Inventory | -15.34 | -3.45 | -0.23 | -2.49 | 0.26 |
Change in Accounts Payable | -13.32 | 12.75 | 1.11 | 1.56 | -0.26 |
Change in Unearned Revenue | 7.77 | -0.68 | 5.09 | 1.51 | - |
Change in Other Net Operating Assets | 1.02 | 8.38 | -1.42 | 2.93 | -1.18 |
Operating Cash Flow | 110.91 | 19.65 | -31.61 | -34.49 | -35.99 |
Operating Cash Flow Growth | 464.34% | - | - | - | - |
Capital Expenditures | -6.16 | -4.74 | -0.78 | -0.85 | -2.86 |
Sale of Property, Plant & Equipment | - | 0.05 | - | - | - |
Sale (Purchase) of Intangibles | -0.14 | -0.17 | - | -0.01 | -0.02 |
Investment in Securities | -49.62 | -488.54 | 33.7 | 19.9 | 55.5 |
Other Investing Activities | 0.92 | -1.09 | 0.66 | -0.85 | -0.33 |
Investing Cash Flow | -55.01 | -494.5 | 33.58 | 18.2 | 52.29 |
Long-Term Debt Repaid | -10.29 | -6.06 | -6.37 | -6.25 | -4.47 |
Net Debt Issued (Repaid) | -10.29 | -6.06 | -6.37 | -6.25 | -4.47 |
Issuance of Common Stock | 0 | 517.68 | 10.69 | 17.7 | - |
Repurchase of Common Stock | -43.02 | -2.37 | - | - | - |
Common Dividends Paid | -41.27 | - | - | - | - |
Other Financing Activities | - | -0.11 | - | - | 0.11 |
Financing Cash Flow | -94.57 | 509.15 | 4.32 | 11.45 | -4.36 |
Net Cash Flow | -38.67 | 34.31 | 6.29 | -4.84 | 11.94 |
Free Cash Flow | 104.74 | 14.91 | -32.39 | -35.33 | -38.85 |
Free Cash Flow Growth | 602.50% | - | - | - | - |
Free Cash Flow Margin | 50.67% | 5.61% | -156.99% | -258.98% | -350.81% |
Free Cash Flow Per Share | 1.32 | 0.21 | -0.58 | -0.64 | -0.72 |
Cash Interest Paid | 1.4 | 0.12 | 0.18 | 0.26 | 0.26 |
Cash Income Tax Paid | 0.46 | 0.09 | -0.02 | -0.06 | -0.05 |
Levered Free Cash Flow | 76.54 | -24.67 | -12.83 | -12.85 | -16.98 |
Unlevered Free Cash Flow | 77.42 | -24.59 | -12.72 | -12.7 | -16.82 |
Change in Working Capital | 24.9 | -101.41 | 4.3 | 3.64 | -0.77 |